Barely Significant
← all excerpts

The role of negative hyperselection in metastatic colorectal cancer.

J Gastrointest Oncol · 2024 · PMC11565117 · PMID 39554588

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

showed a trendP=0.07so close (0.05 < p ≤ 0.1)
When these patients were separated out from the rest of the hyperselection MUT group, the remaining cohort who received Pmab showed a trend towards benefit compared to 5FU/LV alone [median PFS (mPFS) 11.6 vs. 5.0 months, HR =0.41; 95% CI: 0.16–1.05, P=0.07], which may suggest benefit from maintenance Pmab in non- BRAF V600E hyperselection MUT cases.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.